Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended

2022-502188-39-00 Dermatitis atopic 4 2023-09-27
A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante… Ended

2022-502727-21-00 Highly sensitised patients who have undergone kidney tr 5 2023-07-03
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended

2023-504625-39-00 C3 glomerulopathy (C3G) or immune complex membranoproli 5 2023-05-18
Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended

2023-508499-12-00 Systemic Lupus Erythematosus 5 2023-05-17
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended

2023-510081-27-00 Systemic Lupus Erythematosus. 9 2023-02-28
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Intralymfatisk immunterapi förstärkt av vitamin-D, en randomiserad placebokontrollerad studie och jämförelse med SLIT Ended

2024-515271-35-00 Allergisk Rinit 10 2023-02-01
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Eosinophilic esophagitis (EoE) is a rare, chronic infla 5 2023-01-30
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Patients with Paroxysmal Nocturnal Hemoglobinuria 5 2022-12-05
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter c… Ended

2024-517881-40-00 Antineutrophil cytoplasmic antibody (ANCA)- associated 4 2022-11-27
SIRIUS Sarcoidosis with moderate to severe facial skin involvement: an open multicenter study of the efficacy and safety of oral sirolimus Ended

2024-514609-76-00 Adult patients (men and women) (≥ 18 years of age) with 4 2022-11-23
Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended

2023-504740-33-00 Fistulizing perianal Crohn's Disease 5 2022-11-22
The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended

2024-510871-39-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-11-21
RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane… Ended

2024-516168-27-00 Adult patients with persistent or chronic immune thromb 5 2022-11-10
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended

2023-505255-51-00 Herpes Zoster 5 2022-08-08
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Sjögren’s Syndrome 5 2022-08-04
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Lupus nephritis 5 2022-07-14
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended

2023-510019-20-00 Relapsing or refractory Eosinophilic Granulomatosis wit 5 2022-07-13